Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them, rather than a periodic financial report.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. It reports a specific transaction involving the re-investment of dividends under the Company's Deferred Investment Award Programme.
| Metric | Value |
|---|---|
| Transaction Type | Increase in notional interest in Ordinary Shares |
| Instrument | Ordinary shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Price | £16.4900 |
| Transaction Volume | 363.463 shares |
| Transaction Date | July 14, 2016 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses an increase in the notional interest of Ms. C Thomas (SVP, HR) in the company's ordinary shares following dividend re-investment.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory disclosure of a specific share transaction.
Key Facts for Investor Verification
- The filing is a transaction notification for Ms. C Thomas, SVP of HR, not a financial performance report.
- The transaction involved the re-investment of dividends paid on July 14, 2016, into the Deferred Investment Award Programme.
- The transaction price was £16.4900 per share for a volume of 363.463 shares.
- Consolidated financial results for the period are not included in this document.